(Sharecast News) - GSK is planning to cut as many as 350 jobs in research & development in the UK and US, it was announced on Monday.
It was understood the company is planning to axe around 50 roles at its main R&D hub in Stevenage, Hertfordshire.
A spokesperson for the drugs giant said in a statement: "GSK R&D investment has risen by almost 90% over recent years (to £6.4bn in 2024) and we expect it to increase further as we focus on delivering our pipeline of new medicines with multi-blockbuster potential before 2031.
"As we increase investment, we're focused on allocating resources to these priorities and making sure we have the right people in the right teams. Alongside this, we're investing in technology to maximise our scientific capabilities and drive productivity, and in our key R&D sites over the next five years to accelerate drug discovery and research."


(Alliance News) - GSK PLC on Monday launched the fifth tranche of its GBP2.0 billion buyback as it announced an exclusive collaboration with China pha...


(Sharecast News) - Drugmaker GSK said on Monday that it has struck an exclusive agreement with Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pha...


(Alliance News) - Compass Group raised annual profit guidance after reporting double-digit first-half operating profit growth, while GSK announced a C...